Cereno Scientific to present preclinical data for drug candidate CS585 at the AHA Scientific Sessions 2024
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that an abstract on the preclinical drug candidate, novel IP receptor agonist CS585 has been accepted and will be presented at the AHA Scientific Sessions 2024, in Chicago 16–18 November 2024.The abstract titled “Sustained Anti-Thrombotic Efficacy Of CS585, A Novel Prostacyclin Receptor Agonist, Demonstrates Therapeutic Potential”, was authored by L. Stanger, M Flores, P Yalavarthi and M. Holinstat, at University of Michigan, Ann